To evaluate the long-term efficacy and tolerability of a representative extended-release (ER)/long-acting (LA) opioid in a 12-month placebo-controlled trial, FDA staff are considering an enriched ...

If CMS cannot persuade GRAIL of the importance of randomization and using cancer death as the outcome, then it should cancel the study. The magnitude of the problem was evident in a major National ...